Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia

Zanten, Sander Veldhuyzen van; Fedorak, Richard N.; Lambert, Jean; Cohen, Lawrence B.; Vanjaka, Anita

doi:10.1111/j.1572-0241.2003.07583.x

Cited by 20 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Benefits of the eradication of H. pylori have been reported from patients presenting peptic ulcer disease, 2–4 mucosa‐associated lymphoid tissue (MALT) lymphoma 5–7 and gastric adenocarcinoma 8–9 . However, the improvement of symptoms in patients with functional dyspeptic disorder after the eradication of the bacteria remains controversial 10–28 …”

Section: Introductionmentioning

confidence: 99%

“…[8][9] However, the improvement of symptoms in patients with functional dyspeptic disorder after the eradication of the bacteria remains controversial. [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] Epidemiological data show that the prevalence rate of H. pylori in patients without gastro-oesophageal reflux disease (GERD) is slightly higher than in those with the disorder (50 vs. 40%), suggesting a protective role of H. pylori. 29 This is in accordance with other findings: where there is an increasing incidence rate of GERD, Barrett's oesophagus and distal oesophageal adenocarcinoma, there is a parallel decrease in the infection rate of H. pylori.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator‐blinded, placebo‐controlled trial

Ott

Mazzoleni

Edelweiss

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: The protective role of Helicobacter pylori in gastro-oesophageal reflux disease has been widely discussed. Aim: To assess the risk of reflux oesophagitis in patients with functional dyspepsia after treatment for H. pylori infection. Methods: A randomized, placebo-controlled, investigator-blinded trial was carried out on 157 functional dyspeptic patients. Patients were randomized to receive lansoprazole, amoxicillin and clarithromycin (antibiotic group) or lansoprazole and identical antibiotic placebos (control group). Upper gastrointestinal endoscopy was performed at baseline, 3 and 12 months after randomization. The primary aim was to detect the presence of reflux oesophagitis. Analyses were performed on an intention-to-treat basis. Results: A total of 147 patients (94%) and 133 (85%) completed 3 months and 12 months follow-up, respectively. The eradication rate of H. pylori was 90% in the antibiotic group (74 of 82) and 1% (one of 75) in the control group. At 3 months, reflux oesophagitis was diagnosed in 3.7% (three of 82) in the antibiotic group and 4% (three of 75) in the control group (P > 0.2). At 12 months, diagnosis was established in five new cases within the first group and in four within the second (P > 0.2). No difference was found in heartburn symptoms. Conclusions: H. pylori eradication does not cause reflux oesophagitis in this western population of functional dyspeptic patients.

show abstract